Evaluation of putative molecular biomarkers in abdominal and retroperitoneal leiomyosarcomas

European Journal of Surgical Oncology

Volumn 27, Issue 2, 2001, Pages 203-208

  Shpitz, B ^a   Tiomkin, V ^a   Bomstein, Y ^a   Gralkin, M ^a   Buklan, H ^a   Bernheim, J ^a   Klein, E ^a  

^a TEL AVIV UNIVERSITY   (Israel)

Author keywords

Leiomyosarcoma proliferation; Molecular biomarkers

Indexed keywords

BIOLOGICAL MARKER; KI 67 ANTIGEN; MONOCLONAL ANTIBODY KI 67; PARAFFIN; PEROXIDASE; PROTEIN ANTIBODY; PROTEIN BCL 2; PROTEIN P53; STREPTAVIDIN;

ABDOMINAL CANCER; ADULT; AGED; ARTICLE; BLADDER; CANCER GRADING; CANCER LOCALIZATION; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; DEATH; EVALUATION; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; LABELING INDEX; LARGE INTESTINE; LEIOMYOSARCOMA; MALE; MITOSIS RATE; MOLECULAR BIOLOGY; OUTCOMES RESEARCH; PREDICTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; RETROPERITONEAL SARCOMA; RETROPERITONEUM; RETROSPECTIVE STUDY; SMALL INTESTINE; STOMACH; SURVIVAL; SURVIVAL TIME; UTERUS;

EID: 0034937880     PISSN: 07487983     EISSN: None     Source Type: Journal    
DOI: 10.1053/ejso.2000.1074     Document Type: Article

References (30)

1. Common patterns of genetic evolution in human solid tumors
2. Immunohistochemical and molecular genetic approaches to soft tissue tumor diagnosis: A primer
3. The involvement of oncogenes and tumor suppressor genes in the control of apoptosis
4. bcl-2 initiates a new category of oncogenes: Regulators of cell death
5. Apoptosis: Molecular mechanisms and implications for human disease
6. MIB-I expression and iododeoxyuridine labelling in soft tissue sarcomas: An immunohistochemical study including correlations with p53, bcl-2 and histological characteristics
7. Clinical implications of the gene
8. Wild-type p53 is a cell cycle checkpoint determinant following irradiation
9. P53 mutations in human cancers
10. Evaluation of newer prognostic markers in soft tissue sarcomas
11. Proliferative activity (MIB-I index) is an independent prognostic parameter in patients with high-grade soft tissue sarcomas of subtypes other than malignant fibrous histiocytomas: A retrospective 216 soft tissue sarcomas
12. Prognostic relevance of a novel proliferation marker, Ki-SII, for soft-tissue sarcoma
13. Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67
14. Ki-67 detected by MIB-1 predicts distant metastasis and tumor mortality in primary, high grade extremity soft tissue sarcoma
15. Ki-67 and other proliferation markers useful for immunohistological diagnosis and prognostic evaluations in human malignancies
16. Nuclear immunoreaction of p53 protein in soft tissue sarcomas. A possible prognostic factor
17. Prognostic implications of p53 nuclear overexpression and high proliferation index of Ki-67 in adult soft-tissue sarcomas
18. P53, proliferating cell nuclear antigen, and Ki-67 expression in extrauterine leiomyosarcomas
19. Immunohistochemical detection of bcl-2 and p53 proteins and apoptosis in soft tissue sarcoma: Their correlations with prognosis
20. p53 abnormalities in different subtypes of human sarcomas
21. p53 protein expression in non-neoplastic lesions and benign and malignant neoplasms of soft tissue
22. p53 mutation and MDM2 amplification in human soft tissue sarcomas
23. p53 gene mutations and p53 protein expression in human soft tissue sarcomas
24. Expression of bcl-2 oncoprotein in benign and malignant spindle cell tumors of soft tissue, skin, serosal surfaces, and gastrointestinal tract
25. Leiomyosarcoma of the uterus: A clinicopathologic, DNA flow cytometric, p53 and mdm-2. Analysis of 49 cases
26. bcl-2 is preferentially expressed in tumors of muscle origin but is not related to p53 expression
27. c-myc and bcl-2 modulate p53 junction by altering p53 subcellular trafficking during the cell cycle
28. Immunohistochemical detection of p53 and bcl-2 protein in non-Hodgkin's lymphoma
29. bcl-2 and p53 oncoprotein expression during colorectal tumorigenesis
30. The bcl-2 protein: A prognostic indicator strongly related to p53 protein in lymph node-negative breast cancer patients